On March 25, 2025, Rafael Holdings, Inc. completed its merger with Cyclo Therapeutics, Inc., converting Cyclo shares into Rafael Class B common stock at an exchange ratio of 0.3525, resulting in the issuance of approximately 7,132,228 shares of Rafael stock. Additionally, Markus W. Sieger was appointed to Rafael's Board of Directors following the merger.